SEC Form 4 · accession 0001209191-15-005044
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lawrence V Stein
Officer — See Remarks
Period of report
Jan 15, 2015
Accepted (ET)
Jan 20, 2015 · 4:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 15, 2015 | M | 24,124 | $39.33 | A | 30,858 | D | |
| Common StockF1 | Jan 15, 2015 | S | 26,666 | $120.0125 | D | 4,192 | D | |
| Common Stock | holding | — | — | — | 341 | I | 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3,F2 | $39.33 | Jan 15, 2015 | M | 24,124 | D | — | Dec 3, 2022 | Common Stock | 24,124 | 48,250 | D |
Explanation of responses
- F1The price report in Column 4 is a weighted average price. These shares were sold by the reporting person pursuant to a Rule 10b5-1 plan in multiple transactions at prices ranging from $118.62 to $122.41, inclusive. The reporting person undertakes to provide Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F2The option was fully exercisable.
- F3The option was issued pursuant to the Celgene Corporation 2008 Stock Incentive Plan (amended and restated as of April 17, 2013).
Remarks
Executive Vice President, General Counsel and Corporate Secretary